Crossmark

Clinical chemotherapeutic agent coordinated copper-elesclomol nanomedicine potentiates cuproptosis for high-efficiency chemo-immunotherapy of prostate cancer

Crossref DOI link: https://doi.org/10.1007/s10853-026-12190-4

Published Online: 2026-01-16

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Ming

Jiang, Xianzhou

Zhang, Bing

Wang, Zehua

Zhang, Yanhui https://orcid.org/0009-0007-4490-2486
Funding

Funding for this research was provided by:

the Startup Foundation of Qilu Hospital
License Information

Text and Data Mining valid from 2026-01-16

Version of Record valid from 2026-01-16
More Information

Article History

Received: 13 December 2025

Accepted: 7 January 2026

First Online: 16 January 2026

Declarations

:

: The authors declare no conflict of interest.

Document is current

Any future updates will be listed below